Publication: The interest of (18)FDG-PET in the management of testicular cancer
dc.contributor.author | Tofighi, Mojdeh | |
dc.contributor.author | Baillet, Georges | |
dc.contributor.author | Weinmann, Pierre | |
dc.contributor.author | Moretti, Jean Luc | |
dc.contributor.buuauthor | Tamgaç, Feyzi | |
dc.contributor.department | Tıp Fakültesi | |
dc.contributor.orcid | 0000-0002-2325-7728 | |
dc.contributor.scopusid | 35569192500 | |
dc.date.accessioned | 2023-06-12T09:56:17Z | |
dc.date.available | 2023-06-12T09:56:17Z | |
dc.date.issued | 2004-02-28 | |
dc.description.abstract | The key to prognosis initial staging and early recurrence diagnosis are key parameters in the treatment and outcome of testicular cancer. Initial staging. It is difficult using conventional modalities, which can miss node involvement and are non-specific since enlargement does not rime with involvement. (18)FDG PET improves the accuracy of initial staging. Residual mass and recurrences Existence of residual mass or enhancement of its volume in the presence of an otherwise beneficial chemotherapy is difficult to manage. Several studies have demonstrated the value of (18)FDG imaging in such cases. As for follow-up whole body (18)FDG can prevent multiple diagnostic imaging and can diagnose recurrences with greater diagnostic accuracy than with other imaging modalities. | |
dc.identifier.citation | Tamgaç, F. vd. (2004). “The interest of (18)FDG-PET in the management of testicular cancer”. Presse Medicale, 33(4), 270-276. | |
dc.identifier.endpage | 276 | |
dc.identifier.issn | 0755-4982 | |
dc.identifier.issue | 4 | |
dc.identifier.pubmed | 15029020 | |
dc.identifier.scopus | 2-s2.0-1442314360 | |
dc.identifier.startpage | 270 | |
dc.identifier.uri | https://doi.org/10.1016/S0755-4982(04)98554-5 | |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0755498204985545 | |
dc.identifier.uri | http://hdl.handle.net/11452/33006 | |
dc.identifier.volume | 33 | |
dc.identifier.wos | 000189349600016 | |
dc.indexed.wos | SCIE | |
dc.language.iso | en | |
dc.publisher | Masson Editeur | |
dc.relation.collaboration | Yurt dışı | |
dc.relation.journal | Presse Medicale | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | General and internal medicine | |
dc.subject | Positron-emission-tomography | |
dc.subject | Germ-cell tumors | |
dc.subject | Lymph-node metastases | |
dc.subject | Advanced seminoma | |
dc.subject | Residual mass | |
dc.subject | Stage-I | |
dc.subject | FDG PET | |
dc.subject | Chemotherapy | |
dc.subject | Resection | |
dc.subject | Therapy | |
dc.subject.emtree | Cancer chemotherapy | |
dc.subject.emtree | Cancer scintiscanning | |
dc.subject.emtree | Cancer staging | |
dc.subject.emtree | Diagnostic accuracy | |
dc.subject.emtree | Diagnostic error | |
dc.subject.emtree | Diagnostic imaging | |
dc.subject.emtree | Human | |
dc.subject.emtree | Imaging system | |
dc.subject.emtree | Lymph node metastasis | |
dc.subject.emtree | Parameter | |
dc.subject.emtree | Positron emission tomography | |
dc.subject.emtree | Prognosis | |
dc.subject.emtree | Review | |
dc.subject.emtree | Testis cancer | |
dc.subject.emtree | Treatment outcome | |
dc.subject.emtree | Fluorodeoxyglucose F 18 | |
dc.subject.scopus | Lymph Node Dissection; Seminoma; Testicular Germ Cell Tumor | |
dc.subject.wos | Medicine, general and internal | |
dc.title | The interest of (18)FDG-PET in the management of testicular cancer | |
dc.type | Article | |
dc.wos.quartile | Q4 | |
dspace.entity.type | Publication | |
local.contributor.department | Tıp Fakültesi | |
local.indexed.at | PubMed | |
local.indexed.at | WOS |
Files
License bundle
1 - 1 of 1
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: